Effects of linagliptin on left ventricular DYsfunction in patients with type 2 DiAbetes and concentric left ventricular geometry: results of the DYDA 2 trial Article Swipe
Giovanni Cioffi
,
Carlo Giorda
,
Donata Lucci
,
Elisa Nada
,
Federica Ognibeni
,
Costantino Mancusi
,
Roberto Latini
,
Aldo P. Maggioni
·
YOU?
·
· 2020
· Open Access
·
· DOI: https://doi.org/10.1177/2047487320939217
YOU?
·
· 2020
· Open Access
·
· DOI: https://doi.org/10.1177/2047487320939217
Aims To evaluate the effect of linagliptin on left ventricular systolic function beyond glycaemic control in type 2 diabetes mellitus. Methods and results A multicentre, randomised, double-blind, placebo controlled, parallel-group study, was performed (the DYDA 2 trial). Individuals with type 2 diabetes mellitus and asymptomatic impaired left ventricular systolic function were randomly allocated in a 1:1 ratio to receive for 48 weeks either linagliptin 5 mg daily or placebo, in addition to their diabetes therapy. Eligibility criteria were age 40 years and older, haemoglobin A1c 8.0% or less (≤64 mmol/mol), no history of cardiac disease, concentric left ventricular geometry (relative wall thickness ≥0.42), impaired left ventricular systolic function defined as midwall fractional shortening 15% or less at baseline echocardiography. The primary end point was the modification of midwall fractional shortening over time. The main secondary objectives were changes in diastolic and/or in longitudinal left ventricular systolic function as measured by tissue Doppler echocardiography. One hundred and eighty-eight patients were enrolled, predominantly men with typical insulin-resistance comorbidities. At baseline, mean midwall fractional shortening was 13.3%±2.5. At final evaluation, 88 linagliptin patients and 86 placebo patients were compared: midwall fractional shortening increased from 13.29 to 13.82 (+4.1%) in the linagliptin group, from 13.58 to 13.84 in the placebo group (+1.8%, analysis of covariance P = 0.86), corresponding to a 2.3-fold higher increase in linagliptin than the placebo group, although non-statistically significant. Also, changes in diastolic and longitudinal left ventricular systolic function did not differ between the groups. Serious adverse events or linagliptin/placebo permanent discontinuation occurred in very few cases and in the same percentage between the groups. Conclusions In the DYDA 2 patients the addition of linagliptin to stable diabetes therapy was safe and provided a modest non-significant increase in left ventricular systolic function measured as midwall fractional shortening. Trial registration number ClinicalTrial.gov (ID NCT02851745)
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1177/2047487320939217
- https://academic.oup.com/eurjpc/article-pdf/28/1/8/36669468/zwaa434.pdf
- OA Status
- bronze
- Cited By
- 9
- References
- 19
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W3045973615
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W3045973615Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1177/2047487320939217Digital Object Identifier
- Title
-
Effects of linagliptin on left ventricular DYsfunction in patients with type 2 DiAbetes and concentric left ventricular geometry: results of the DYDA 2 trialWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2020Year of publication
- Publication date
-
2020-07-28Full publication date if available
- Authors
-
Giovanni Cioffi, Carlo Giorda, Donata Lucci, Elisa Nada, Federica Ognibeni, Costantino Mancusi, Roberto Latini, Aldo P. MaggioniList of authors in order
- Landing page
-
https://doi.org/10.1177/2047487320939217Publisher landing page
- PDF URL
-
https://academic.oup.com/eurjpc/article-pdf/28/1/8/36669468/zwaa434.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
bronzeOpen access status per OpenAlex
- OA URL
-
https://academic.oup.com/eurjpc/article-pdf/28/1/8/36669468/zwaa434.pdfDirect OA link when available
- Concepts
-
Medicine, Cardiology, Internal medicine, Placebo, Linagliptin, Diastole, Diabetes mellitus, Asymptomatic, Type 2 Diabetes Mellitus, Blood pressure, Endocrinology, Pathology, Alternative medicineTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
9Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 2, 2024: 3, 2023: 2, 2021: 1, 2020: 1Per-year citation counts (last 5 years)
- References (count)
-
19Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W3045973615 |
|---|---|
| doi | https://doi.org/10.1177/2047487320939217 |
| ids.doi | https://doi.org/10.1177/2047487320939217 |
| ids.mag | 3045973615 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/33755143 |
| ids.openalex | https://openalex.org/W3045973615 |
| fwci | 0.72133247 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D000328 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Adult |
| mesh[1].qualifier_ui | Q000150 |
| mesh[1].descriptor_ui | D003924 |
| mesh[1].is_major_topic | True |
| mesh[1].qualifier_name | complications |
| mesh[1].descriptor_name | Diabetes Mellitus, Type 2 |
| mesh[2].qualifier_ui | Q000175 |
| mesh[2].descriptor_ui | D003924 |
| mesh[2].is_major_topic | True |
| mesh[2].qualifier_name | diagnosis |
| mesh[2].descriptor_name | Diabetes Mellitus, Type 2 |
| mesh[3].qualifier_ui | Q000188 |
| mesh[3].descriptor_ui | D003924 |
| mesh[3].is_major_topic | True |
| mesh[3].qualifier_name | drug therapy |
| mesh[3].descriptor_name | Diabetes Mellitus, Type 2 |
| mesh[4].qualifier_ui | |
| mesh[4].descriptor_ui | D004311 |
| mesh[4].is_major_topic | False |
| mesh[4].qualifier_name | |
| mesh[4].descriptor_name | Double-Blind Method |
| mesh[5].qualifier_ui | |
| mesh[5].descriptor_ui | D005260 |
| mesh[5].is_major_topic | False |
| mesh[5].qualifier_name | |
| mesh[5].descriptor_name | Female |
| mesh[6].qualifier_ui | |
| mesh[6].descriptor_ui | D006442 |
| mesh[6].is_major_topic | False |
| mesh[6].qualifier_name | |
| mesh[6].descriptor_name | Glycated Hemoglobin |
| mesh[7].qualifier_ui | |
| mesh[7].descriptor_ui | D006801 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | |
| mesh[7].descriptor_name | Humans |
| mesh[8].qualifier_ui | Q000009 |
| mesh[8].descriptor_ui | D000069476 |
| mesh[8].is_major_topic | False |
| mesh[8].qualifier_name | adverse effects |
| mesh[8].descriptor_name | Linagliptin |
| mesh[9].qualifier_ui | |
| mesh[9].descriptor_ui | D008297 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | |
| mesh[9].descriptor_name | Male |
| mesh[10].qualifier_ui | Q000000981 |
| mesh[10].descriptor_ui | D018487 |
| mesh[10].is_major_topic | True |
| mesh[10].qualifier_name | diagnostic imaging |
| mesh[10].descriptor_name | Ventricular Dysfunction, Left |
| mesh[11].qualifier_ui | Q000188 |
| mesh[11].descriptor_ui | D018487 |
| mesh[11].is_major_topic | True |
| mesh[11].qualifier_name | drug therapy |
| mesh[11].descriptor_name | Ventricular Dysfunction, Left |
| mesh[12].qualifier_ui | Q000209 |
| mesh[12].descriptor_ui | D018487 |
| mesh[12].is_major_topic | True |
| mesh[12].qualifier_name | etiology |
| mesh[12].descriptor_name | Ventricular Dysfunction, Left |
| mesh[13].qualifier_ui | |
| mesh[13].descriptor_ui | D016277 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | |
| mesh[13].descriptor_name | Ventricular Function, Left |
| mesh[14].qualifier_ui | |
| mesh[14].descriptor_ui | D000328 |
| mesh[14].is_major_topic | False |
| mesh[14].qualifier_name | |
| mesh[14].descriptor_name | Adult |
| mesh[15].qualifier_ui | Q000150 |
| mesh[15].descriptor_ui | D003924 |
| mesh[15].is_major_topic | True |
| mesh[15].qualifier_name | complications |
| mesh[15].descriptor_name | Diabetes Mellitus, Type 2 |
| mesh[16].qualifier_ui | Q000175 |
| mesh[16].descriptor_ui | D003924 |
| mesh[16].is_major_topic | True |
| mesh[16].qualifier_name | diagnosis |
| mesh[16].descriptor_name | Diabetes Mellitus, Type 2 |
| mesh[17].qualifier_ui | Q000188 |
| mesh[17].descriptor_ui | D003924 |
| mesh[17].is_major_topic | True |
| mesh[17].qualifier_name | drug therapy |
| mesh[17].descriptor_name | Diabetes Mellitus, Type 2 |
| mesh[18].qualifier_ui | |
| mesh[18].descriptor_ui | D004311 |
| mesh[18].is_major_topic | False |
| mesh[18].qualifier_name | |
| mesh[18].descriptor_name | Double-Blind Method |
| mesh[19].qualifier_ui | |
| mesh[19].descriptor_ui | D005260 |
| mesh[19].is_major_topic | False |
| mesh[19].qualifier_name | |
| mesh[19].descriptor_name | Female |
| mesh[20].qualifier_ui | |
| mesh[20].descriptor_ui | D006442 |
| mesh[20].is_major_topic | False |
| mesh[20].qualifier_name | |
| mesh[20].descriptor_name | Glycated Hemoglobin |
| mesh[21].qualifier_ui | |
| mesh[21].descriptor_ui | D006801 |
| mesh[21].is_major_topic | False |
| mesh[21].qualifier_name | |
| mesh[21].descriptor_name | Humans |
| mesh[22].qualifier_ui | Q000009 |
| mesh[22].descriptor_ui | D000069476 |
| mesh[22].is_major_topic | False |
| mesh[22].qualifier_name | adverse effects |
| mesh[22].descriptor_name | Linagliptin |
| mesh[23].qualifier_ui | |
| mesh[23].descriptor_ui | D008297 |
| mesh[23].is_major_topic | False |
| mesh[23].qualifier_name | |
| mesh[23].descriptor_name | Male |
| mesh[24].qualifier_ui | Q000000981 |
| mesh[24].descriptor_ui | D018487 |
| mesh[24].is_major_topic | True |
| mesh[24].qualifier_name | diagnostic imaging |
| mesh[24].descriptor_name | Ventricular Dysfunction, Left |
| mesh[25].qualifier_ui | Q000188 |
| mesh[25].descriptor_ui | D018487 |
| mesh[25].is_major_topic | True |
| mesh[25].qualifier_name | drug therapy |
| mesh[25].descriptor_name | Ventricular Dysfunction, Left |
| mesh[26].qualifier_ui | Q000209 |
| mesh[26].descriptor_ui | D018487 |
| mesh[26].is_major_topic | True |
| mesh[26].qualifier_name | etiology |
| mesh[26].descriptor_name | Ventricular Dysfunction, Left |
| mesh[27].qualifier_ui | |
| mesh[27].descriptor_ui | D016277 |
| mesh[27].is_major_topic | False |
| mesh[27].qualifier_name | |
| mesh[27].descriptor_name | Ventricular Function, Left |
| type | article |
| title | Effects of linagliptin on left ventricular DYsfunction in patients with type 2 DiAbetes and concentric left ventricular geometry: results of the DYDA 2 trial |
| biblio.issue | 1 |
| biblio.volume | 28 |
| biblio.last_page | 17 |
| biblio.first_page | 8 |
| topics[0].id | https://openalex.org/T10401 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9998999834060669 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2712 |
| topics[0].subfield.display_name | Endocrinology, Diabetes and Metabolism |
| topics[0].display_name | Diabetes Treatment and Management |
| topics[1].id | https://openalex.org/T10821 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9986000061035156 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2705 |
| topics[1].subfield.display_name | Cardiology and Cardiovascular Medicine |
| topics[1].display_name | Cardiovascular Function and Risk Factors |
| topics[2].id | https://openalex.org/T11339 |
| topics[2].field.id | https://openalex.org/fields/13 |
| topics[2].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[2].score | 0.9914000034332275 |
| topics[2].domain.id | https://openalex.org/domains/1 |
| topics[2].domain.display_name | Life Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/1312 |
| topics[2].subfield.display_name | Molecular Biology |
| topics[2].display_name | Metabolism, Diabetes, and Cancer |
| is_xpac | False |
| apc_list.value | 3014 |
| apc_list.currency | EUR |
| apc_list.value_usd | 3250 |
| apc_paid | |
| concepts[0].id | https://openalex.org/C71924100 |
| concepts[0].level | 0 |
| concepts[0].score | 0.9129563570022583 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[0].display_name | Medicine |
| concepts[1].id | https://openalex.org/C164705383 |
| concepts[1].level | 1 |
| concepts[1].score | 0.7019846439361572 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q10379 |
| concepts[1].display_name | Cardiology |
| concepts[2].id | https://openalex.org/C126322002 |
| concepts[2].level | 1 |
| concepts[2].score | 0.6994044184684753 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[2].display_name | Internal medicine |
| concepts[3].id | https://openalex.org/C27081682 |
| concepts[3].level | 3 |
| concepts[3].score | 0.6861618161201477 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q269829 |
| concepts[3].display_name | Placebo |
| concepts[4].id | https://openalex.org/C2780031085 |
| concepts[4].level | 4 |
| concepts[4].score | 0.665799617767334 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q909745 |
| concepts[4].display_name | Linagliptin |
| concepts[5].id | https://openalex.org/C57900726 |
| concepts[5].level | 3 |
| concepts[5].score | 0.5285826325416565 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q492905 |
| concepts[5].display_name | Diastole |
| concepts[6].id | https://openalex.org/C555293320 |
| concepts[6].level | 2 |
| concepts[6].score | 0.5244489312171936 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q12206 |
| concepts[6].display_name | Diabetes mellitus |
| concepts[7].id | https://openalex.org/C2777910003 |
| concepts[7].level | 2 |
| concepts[7].score | 0.4275383949279785 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q1707292 |
| concepts[7].display_name | Asymptomatic |
| concepts[8].id | https://openalex.org/C2910068830 |
| concepts[8].level | 3 |
| concepts[8].score | 0.35847151279449463 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q3025883 |
| concepts[8].display_name | Type 2 Diabetes Mellitus |
| concepts[9].id | https://openalex.org/C84393581 |
| concepts[9].level | 2 |
| concepts[9].score | 0.23295897245407104 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q82642 |
| concepts[9].display_name | Blood pressure |
| concepts[10].id | https://openalex.org/C134018914 |
| concepts[10].level | 1 |
| concepts[10].score | 0.16537830233573914 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q162606 |
| concepts[10].display_name | Endocrinology |
| concepts[11].id | https://openalex.org/C142724271 |
| concepts[11].level | 1 |
| concepts[11].score | 0.0 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q7208 |
| concepts[11].display_name | Pathology |
| concepts[12].id | https://openalex.org/C204787440 |
| concepts[12].level | 2 |
| concepts[12].score | 0.0 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q188504 |
| concepts[12].display_name | Alternative medicine |
| keywords[0].id | https://openalex.org/keywords/medicine |
| keywords[0].score | 0.9129563570022583 |
| keywords[0].display_name | Medicine |
| keywords[1].id | https://openalex.org/keywords/cardiology |
| keywords[1].score | 0.7019846439361572 |
| keywords[1].display_name | Cardiology |
| keywords[2].id | https://openalex.org/keywords/internal-medicine |
| keywords[2].score | 0.6994044184684753 |
| keywords[2].display_name | Internal medicine |
| keywords[3].id | https://openalex.org/keywords/placebo |
| keywords[3].score | 0.6861618161201477 |
| keywords[3].display_name | Placebo |
| keywords[4].id | https://openalex.org/keywords/linagliptin |
| keywords[4].score | 0.665799617767334 |
| keywords[4].display_name | Linagliptin |
| keywords[5].id | https://openalex.org/keywords/diastole |
| keywords[5].score | 0.5285826325416565 |
| keywords[5].display_name | Diastole |
| keywords[6].id | https://openalex.org/keywords/diabetes-mellitus |
| keywords[6].score | 0.5244489312171936 |
| keywords[6].display_name | Diabetes mellitus |
| keywords[7].id | https://openalex.org/keywords/asymptomatic |
| keywords[7].score | 0.4275383949279785 |
| keywords[7].display_name | Asymptomatic |
| keywords[8].id | https://openalex.org/keywords/type-2-diabetes-mellitus |
| keywords[8].score | 0.35847151279449463 |
| keywords[8].display_name | Type 2 Diabetes Mellitus |
| keywords[9].id | https://openalex.org/keywords/blood-pressure |
| keywords[9].score | 0.23295897245407104 |
| keywords[9].display_name | Blood pressure |
| keywords[10].id | https://openalex.org/keywords/endocrinology |
| keywords[10].score | 0.16537830233573914 |
| keywords[10].display_name | Endocrinology |
| language | en |
| locations[0].id | doi:10.1177/2047487320939217 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S201064403 |
| locations[0].source.issn | 2047-4873, 2047-4881 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 2047-4873 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | European Journal of Preventive Cardiology |
| locations[0].source.host_organization | https://openalex.org/P4310311648 |
| locations[0].source.host_organization_name | Oxford University Press |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310311648, https://openalex.org/P4310311647 |
| locations[0].source.host_organization_lineage_names | Oxford University Press, University of Oxford |
| locations[0].license | |
| locations[0].pdf_url | https://academic.oup.com/eurjpc/article-pdf/28/1/8/36669468/zwaa434.pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | European Journal of Preventive Cardiology |
| locations[0].landing_page_url | https://doi.org/10.1177/2047487320939217 |
| locations[1].id | pmid:33755143 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | European journal of preventive cardiology |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/33755143 |
| indexed_in | crossref, pubmed |
| authorships[0].author.id | https://openalex.org/A5083250453 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-2805-9982 |
| authorships[0].author.display_name | Giovanni Cioffi |
| authorships[0].countries | IT |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I4210094363 |
| authorships[0].affiliations[0].raw_affiliation_string | Division of Rheumatology, University and Azienda Ospedaliera Universitaria Integrata of Verona , Italy |
| authorships[0].institutions[0].id | https://openalex.org/I4210094363 |
| authorships[0].institutions[0].ror | https://ror.org/00sm8k518 |
| authorships[0].institutions[0].type | healthcare |
| authorships[0].institutions[0].lineage | https://openalex.org/I4210094363 |
| authorships[0].institutions[0].country_code | IT |
| authorships[0].institutions[0].display_name | Azienda Ospedaliera Universitaria Integrata Verona |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Giovanni Cioffi |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Division of Rheumatology, University and Azienda Ospedaliera Universitaria Integrata of Verona , Italy |
| authorships[1].author.id | https://openalex.org/A5038036766 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-4709-8696 |
| authorships[1].author.display_name | Carlo Giorda |
| authorships[1].countries | IT |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I4210128445 |
| authorships[1].affiliations[0].raw_affiliation_string | Metabolism and Diabetes Unit, ASL Torino 5 , Italy |
| authorships[1].institutions[0].id | https://openalex.org/I4210128445 |
| authorships[1].institutions[0].ror | https://ror.org/03cxxc369 |
| authorships[1].institutions[0].type | facility |
| authorships[1].institutions[0].lineage | https://openalex.org/I4210128445 |
| authorships[1].institutions[0].country_code | IT |
| authorships[1].institutions[0].display_name | Torino e-district |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Carlo Bruno Giorda |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Metabolism and Diabetes Unit, ASL Torino 5 , Italy |
| authorships[2].author.id | https://openalex.org/A5090865092 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-8614-785X |
| authorships[2].author.display_name | Donata Lucci |
| authorships[2].countries | IT |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I4210095959 |
| authorships[2].affiliations[0].raw_affiliation_string | ANMCO Research Center, Heart Care Foundation , Italy |
| authorships[2].institutions[0].id | https://openalex.org/I4210095959 |
| authorships[2].institutions[0].ror | https://ror.org/00pyc4352 |
| authorships[2].institutions[0].type | nonprofit |
| authorships[2].institutions[0].lineage | https://openalex.org/I4210095959 |
| authorships[2].institutions[0].country_code | IT |
| authorships[2].institutions[0].display_name | Associazione Nazionale Medici Cardiologi Ospedalieri |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Donata Lucci |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | ANMCO Research Center, Heart Care Foundation , Italy |
| authorships[3].author.id | https://openalex.org/A5071855267 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-0765-5208 |
| authorships[3].author.display_name | Elisa Nada |
| authorships[3].countries | IT |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I4210128445 |
| authorships[3].affiliations[0].raw_affiliation_string | Metabolism and Diabetes Unit, ASL Torino 5 , Italy |
| authorships[3].institutions[0].id | https://openalex.org/I4210128445 |
| authorships[3].institutions[0].ror | https://ror.org/03cxxc369 |
| authorships[3].institutions[0].type | facility |
| authorships[3].institutions[0].lineage | https://openalex.org/I4210128445 |
| authorships[3].institutions[0].country_code | IT |
| authorships[3].institutions[0].display_name | Torino e-district |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Elisa Nada |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Metabolism and Diabetes Unit, ASL Torino 5 , Italy |
| authorships[4].author.id | https://openalex.org/A5113907018 |
| authorships[4].author.orcid | |
| authorships[4].author.display_name | Federica Ognibeni |
| authorships[4].countries | IT |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I4210094363 |
| authorships[4].affiliations[0].raw_affiliation_string | Division of Rheumatology, University and Azienda Ospedaliera Universitaria Integrata of Verona , Italy |
| authorships[4].institutions[0].id | https://openalex.org/I4210094363 |
| authorships[4].institutions[0].ror | https://ror.org/00sm8k518 |
| authorships[4].institutions[0].type | healthcare |
| authorships[4].institutions[0].lineage | https://openalex.org/I4210094363 |
| authorships[4].institutions[0].country_code | IT |
| authorships[4].institutions[0].display_name | Azienda Ospedaliera Universitaria Integrata Verona |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Federica Ognibeni |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Division of Rheumatology, University and Azienda Ospedaliera Universitaria Integrata of Verona , Italy |
| authorships[5].author.id | https://openalex.org/A5103207733 |
| authorships[5].author.orcid | |
| authorships[5].author.display_name | Costantino Mancusi |
| authorships[5].countries | IT |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I4210117450 |
| authorships[5].affiliations[0].raw_affiliation_string | Hypertension Research Center, Federico II University , Italy |
| authorships[5].institutions[0].id | https://openalex.org/I4210117450 |
| authorships[5].institutions[0].ror | https://ror.org/02jr6tp70 |
| authorships[5].institutions[0].type | healthcare |
| authorships[5].institutions[0].lineage | https://openalex.org/I4210117450, https://openalex.org/I71267560 |
| authorships[5].institutions[0].country_code | IT |
| authorships[5].institutions[0].display_name | Federico II University Hospital |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Costantino Mancusi |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Hypertension Research Center, Federico II University , Italy |
| authorships[6].author.id | https://openalex.org/A5027518592 |
| authorships[6].author.orcid | https://orcid.org/0000-0002-3729-4650 |
| authorships[6].author.display_name | Roberto Latini |
| authorships[6].countries | IT |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I19630809, https://openalex.org/I4210153126 |
| authorships[6].affiliations[0].raw_affiliation_string | Department of Cardiovascular Research, IRCCS Istituto di Ricerche Farmacologiche “Mario Negri” , Italy |
| authorships[6].institutions[0].id | https://openalex.org/I4210153126 |
| authorships[6].institutions[0].ror | https://ror.org/04tfzc498 |
| authorships[6].institutions[0].type | healthcare |
| authorships[6].institutions[0].lineage | https://openalex.org/I4210153126 |
| authorships[6].institutions[0].country_code | IT |
| authorships[6].institutions[0].display_name | Istituti di Ricovero e Cura a Carattere Scientifico |
| authorships[6].institutions[1].id | https://openalex.org/I19630809 |
| authorships[6].institutions[1].ror | https://ror.org/05aspc753 |
| authorships[6].institutions[1].type | nonprofit |
| authorships[6].institutions[1].lineage | https://openalex.org/I19630809, https://openalex.org/I4210110338, https://openalex.org/I4210153126 |
| authorships[6].institutions[1].country_code | IT |
| authorships[6].institutions[1].display_name | Mario Negri Institute for Pharmacological Research |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Roberto Latini |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Department of Cardiovascular Research, IRCCS Istituto di Ricerche Farmacologiche “Mario Negri” , Italy |
| authorships[7].author.id | https://openalex.org/A5088186128 |
| authorships[7].author.orcid | https://orcid.org/0000-0003-2764-6779 |
| authorships[7].author.display_name | Aldo P. Maggioni |
| authorships[7].countries | IT |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I4210095959 |
| authorships[7].affiliations[0].raw_affiliation_string | ANMCO Research Center, Heart Care Foundation , Italy |
| authorships[7].institutions[0].id | https://openalex.org/I4210095959 |
| authorships[7].institutions[0].ror | https://ror.org/00pyc4352 |
| authorships[7].institutions[0].type | nonprofit |
| authorships[7].institutions[0].lineage | https://openalex.org/I4210095959 |
| authorships[7].institutions[0].country_code | IT |
| authorships[7].institutions[0].display_name | Associazione Nazionale Medici Cardiologi Ospedalieri |
| authorships[7].author_position | last |
| authorships[7].raw_author_name | Aldo P Maggioni |
| authorships[7].is_corresponding | True |
| authorships[7].raw_affiliation_strings | ANMCO Research Center, Heart Care Foundation , Italy |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://academic.oup.com/eurjpc/article-pdf/28/1/8/36669468/zwaa434.pdf |
| open_access.oa_status | bronze |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Effects of linagliptin on left ventricular DYsfunction in patients with type 2 DiAbetes and concentric left ventricular geometry: results of the DYDA 2 trial |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10401 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9998999834060669 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2712 |
| primary_topic.subfield.display_name | Endocrinology, Diabetes and Metabolism |
| primary_topic.display_name | Diabetes Treatment and Management |
| related_works | https://openalex.org/W2314618592, https://openalex.org/W2253571467, https://openalex.org/W2110972117, https://openalex.org/W1206097261, https://openalex.org/W2770628467, https://openalex.org/W2089118765, https://openalex.org/W1597594434, https://openalex.org/W3160546082, https://openalex.org/W2379747457, https://openalex.org/W1851495633 |
| cited_by_count | 9 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 2 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 3 |
| counts_by_year[2].year | 2023 |
| counts_by_year[2].cited_by_count | 2 |
| counts_by_year[3].year | 2021 |
| counts_by_year[3].cited_by_count | 1 |
| counts_by_year[4].year | 2020 |
| counts_by_year[4].cited_by_count | 1 |
| locations_count | 2 |
| best_oa_location.id | doi:10.1177/2047487320939217 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S201064403 |
| best_oa_location.source.issn | 2047-4873, 2047-4881 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 2047-4873 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | European Journal of Preventive Cardiology |
| best_oa_location.source.host_organization | https://openalex.org/P4310311648 |
| best_oa_location.source.host_organization_name | Oxford University Press |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310311648, https://openalex.org/P4310311647 |
| best_oa_location.source.host_organization_lineage_names | Oxford University Press, University of Oxford |
| best_oa_location.license | |
| best_oa_location.pdf_url | https://academic.oup.com/eurjpc/article-pdf/28/1/8/36669468/zwaa434.pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | European Journal of Preventive Cardiology |
| best_oa_location.landing_page_url | https://doi.org/10.1177/2047487320939217 |
| primary_location.id | doi:10.1177/2047487320939217 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S201064403 |
| primary_location.source.issn | 2047-4873, 2047-4881 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 2047-4873 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | European Journal of Preventive Cardiology |
| primary_location.source.host_organization | https://openalex.org/P4310311648 |
| primary_location.source.host_organization_name | Oxford University Press |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310311648, https://openalex.org/P4310311647 |
| primary_location.source.host_organization_lineage_names | Oxford University Press, University of Oxford |
| primary_location.license | |
| primary_location.pdf_url | https://academic.oup.com/eurjpc/article-pdf/28/1/8/36669468/zwaa434.pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | European Journal of Preventive Cardiology |
| primary_location.landing_page_url | https://doi.org/10.1177/2047487320939217 |
| publication_date | 2020-07-28 |
| publication_year | 2020 |
| referenced_works | https://openalex.org/W2140480989, https://openalex.org/W2074142099, https://openalex.org/W2035274147, https://openalex.org/W2063040422, https://openalex.org/W130204912, https://openalex.org/W2160286139, https://openalex.org/W2033316662, https://openalex.org/W2064130493, https://openalex.org/W2118619033, https://openalex.org/W2968278146, https://openalex.org/W2136337858, https://openalex.org/W2100872366, https://openalex.org/W1270972166, https://openalex.org/W2040109222, https://openalex.org/W2044026856, https://openalex.org/W2142830692, https://openalex.org/W2900149048, https://openalex.org/W2894993577, https://openalex.org/W2886991044 |
| referenced_works_count | 19 |
| abstract_inverted_index.2 | 18, 36, 41, 270 |
| abstract_inverted_index.5 | 65 |
| abstract_inverted_index.= | 213 |
| abstract_inverted_index.A | 24 |
| abstract_inverted_index.P | 212 |
| abstract_inverted_index.a | 55, 217, 284 |
| abstract_inverted_index.40 | 80 |
| abstract_inverted_index.48 | 61 |
| abstract_inverted_index.86 | 182 |
| abstract_inverted_index.88 | 178 |
| abstract_inverted_index.At | 167, 175 |
| abstract_inverted_index.In | 267 |
| abstract_inverted_index.To | 2 |
| abstract_inverted_index.as | 110, 148, 294 |
| abstract_inverted_index.at | 117 |
| abstract_inverted_index.by | 150 |
| abstract_inverted_index.in | 16, 54, 70, 139, 142, 196, 204, 221, 232, 254, 259, 288 |
| abstract_inverted_index.mg | 66 |
| abstract_inverted_index.no | 91 |
| abstract_inverted_index.of | 6, 93, 127, 210, 274 |
| abstract_inverted_index.on | 8 |
| abstract_inverted_index.or | 68, 87, 115, 249 |
| abstract_inverted_index.to | 58, 72, 193, 202, 216, 276 |
| abstract_inverted_index.(ID | 302 |
| abstract_inverted_index.15% | 114 |
| abstract_inverted_index.1:1 | 56 |
| abstract_inverted_index.A1c | 85 |
| abstract_inverted_index.One | 154 |
| abstract_inverted_index.The | 120, 133 |
| abstract_inverted_index.age | 79 |
| abstract_inverted_index.and | 22, 44, 82, 156, 181, 234, 258, 282 |
| abstract_inverted_index.did | 240 |
| abstract_inverted_index.end | 122 |
| abstract_inverted_index.few | 256 |
| abstract_inverted_index.for | 60 |
| abstract_inverted_index.men | 162 |
| abstract_inverted_index.not | 241 |
| abstract_inverted_index.the | 4, 125, 197, 205, 224, 244, 260, 264, 268, 272 |
| abstract_inverted_index.was | 32, 124, 173, 280 |
| abstract_inverted_index.(the | 34 |
| abstract_inverted_index.8.0% | 86 |
| abstract_inverted_index.Aims | 1 |
| abstract_inverted_index.DYDA | 35, 269 |
| abstract_inverted_index.from | 191, 200 |
| abstract_inverted_index.left | 9, 47, 97, 105, 144, 236, 289 |
| abstract_inverted_index.less | 88, 116 |
| abstract_inverted_index.main | 134 |
| abstract_inverted_index.mean | 169 |
| abstract_inverted_index.over | 131 |
| abstract_inverted_index.safe | 281 |
| abstract_inverted_index.same | 261 |
| abstract_inverted_index.than | 223 |
| abstract_inverted_index.type | 17, 40 |
| abstract_inverted_index.very | 255 |
| abstract_inverted_index.wall | 101 |
| abstract_inverted_index.were | 51, 78, 137, 159, 185 |
| abstract_inverted_index.with | 39, 163 |
| abstract_inverted_index.13.29 | 192 |
| abstract_inverted_index.13.58 | 201 |
| abstract_inverted_index.13.82 | 194 |
| abstract_inverted_index.13.84 | 203 |
| abstract_inverted_index.Also, | 230 |
| abstract_inverted_index.Trial | 298 |
| abstract_inverted_index.cases | 257 |
| abstract_inverted_index.daily | 67 |
| abstract_inverted_index.final | 176 |
| abstract_inverted_index.group | 207 |
| abstract_inverted_index.point | 123 |
| abstract_inverted_index.ratio | 57 |
| abstract_inverted_index.their | 73 |
| abstract_inverted_index.time. | 132 |
| abstract_inverted_index.weeks | 62 |
| abstract_inverted_index.years | 81 |
| abstract_inverted_index.(≤64 | 89 |
| abstract_inverted_index.0.86), | 214 |
| abstract_inverted_index.and/or | 141 |
| abstract_inverted_index.beyond | 13 |
| abstract_inverted_index.differ | 242 |
| abstract_inverted_index.effect | 5 |
| abstract_inverted_index.either | 63 |
| abstract_inverted_index.events | 248 |
| abstract_inverted_index.group, | 199, 226 |
| abstract_inverted_index.higher | 219 |
| abstract_inverted_index.modest | 285 |
| abstract_inverted_index.number | 300 |
| abstract_inverted_index.older, | 83 |
| abstract_inverted_index.stable | 277 |
| abstract_inverted_index.study, | 31 |
| abstract_inverted_index.tissue | 151 |
| abstract_inverted_index.(+1.8%, | 208 |
| abstract_inverted_index.(+4.1%) | 195 |
| abstract_inverted_index.Doppler | 152 |
| abstract_inverted_index.Methods | 21 |
| abstract_inverted_index.Serious | 246 |
| abstract_inverted_index.adverse | 247 |
| abstract_inverted_index.between | 243, 263 |
| abstract_inverted_index.cardiac | 94 |
| abstract_inverted_index.changes | 138, 231 |
| abstract_inverted_index.control | 15 |
| abstract_inverted_index.defined | 109 |
| abstract_inverted_index.groups. | 245, 265 |
| abstract_inverted_index.history | 92 |
| abstract_inverted_index.hundred | 155 |
| abstract_inverted_index.midwall | 111, 128, 170, 187, 295 |
| abstract_inverted_index.placebo | 28, 183, 206, 225 |
| abstract_inverted_index.primary | 121 |
| abstract_inverted_index.receive | 59 |
| abstract_inverted_index.results | 23 |
| abstract_inverted_index.therapy | 279 |
| abstract_inverted_index.trial). | 37 |
| abstract_inverted_index.typical | 164 |
| abstract_inverted_index.2.3-fold | 218 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.addition | 71, 273 |
| abstract_inverted_index.although | 227 |
| abstract_inverted_index.analysis | 209 |
| abstract_inverted_index.baseline | 118 |
| abstract_inverted_index.criteria | 77 |
| abstract_inverted_index.diabetes | 19, 42, 74, 278 |
| abstract_inverted_index.disease, | 95 |
| abstract_inverted_index.evaluate | 3 |
| abstract_inverted_index.function | 12, 50, 108, 147, 239, 292 |
| abstract_inverted_index.geometry | 99 |
| abstract_inverted_index.impaired | 46, 104 |
| abstract_inverted_index.increase | 220, 287 |
| abstract_inverted_index.measured | 149, 293 |
| abstract_inverted_index.mellitus | 43 |
| abstract_inverted_index.occurred | 253 |
| abstract_inverted_index.patients | 158, 180, 184, 271 |
| abstract_inverted_index.placebo, | 69 |
| abstract_inverted_index.provided | 283 |
| abstract_inverted_index.randomly | 52 |
| abstract_inverted_index.systolic | 11, 49, 107, 146, 238, 291 |
| abstract_inverted_index.therapy. | 75 |
| abstract_inverted_index.(relative | 100 |
| abstract_inverted_index.allocated | 53 |
| abstract_inverted_index.baseline, | 168 |
| abstract_inverted_index.compared: | 186 |
| abstract_inverted_index.diastolic | 140, 233 |
| abstract_inverted_index.enrolled, | 160 |
| abstract_inverted_index.glycaemic | 14 |
| abstract_inverted_index.increased | 190 |
| abstract_inverted_index.mellitus. | 20 |
| abstract_inverted_index.performed | 33 |
| abstract_inverted_index.permanent | 251 |
| abstract_inverted_index.secondary | 135 |
| abstract_inverted_index.thickness | 102 |
| abstract_inverted_index.≥0.42), | 103 |
| abstract_inverted_index.concentric | 96 |
| abstract_inverted_index.covariance | 211 |
| abstract_inverted_index.fractional | 112, 129, 171, 188, 296 |
| abstract_inverted_index.mmol/mol), | 90 |
| abstract_inverted_index.objectives | 136 |
| abstract_inverted_index.percentage | 262 |
| abstract_inverted_index.shortening | 113, 130, 172, 189 |
| abstract_inverted_index.13.3%±2.5. | 174 |
| abstract_inverted_index.Conclusions | 266 |
| abstract_inverted_index.Eligibility | 76 |
| abstract_inverted_index.Individuals | 38 |
| abstract_inverted_index.controlled, | 29 |
| abstract_inverted_index.evaluation, | 177 |
| abstract_inverted_index.haemoglobin | 84 |
| abstract_inverted_index.linagliptin | 7, 64, 179, 198, 222, 275 |
| abstract_inverted_index.randomised, | 26 |
| abstract_inverted_index.shortening. | 297 |
| abstract_inverted_index.ventricular | 10, 48, 98, 106, 145, 237, 290 |
| abstract_inverted_index.NCT02851745) | 303 |
| abstract_inverted_index.asymptomatic | 45 |
| abstract_inverted_index.eighty-eight | 157 |
| abstract_inverted_index.longitudinal | 143, 235 |
| abstract_inverted_index.modification | 126 |
| abstract_inverted_index.multicentre, | 25 |
| abstract_inverted_index.registration | 299 |
| abstract_inverted_index.significant. | 229 |
| abstract_inverted_index.corresponding | 215 |
| abstract_inverted_index.double-blind, | 27 |
| abstract_inverted_index.predominantly | 161 |
| abstract_inverted_index.comorbidities. | 166 |
| abstract_inverted_index.parallel-group | 30 |
| abstract_inverted_index.discontinuation | 252 |
| abstract_inverted_index.non-significant | 286 |
| abstract_inverted_index.ClinicalTrial.gov | 301 |
| abstract_inverted_index.echocardiography. | 119, 153 |
| abstract_inverted_index.non-statistically | 228 |
| abstract_inverted_index.insulin-resistance | 165 |
| abstract_inverted_index.linagliptin/placebo | 250 |
| cited_by_percentile_year.max | 97 |
| cited_by_percentile_year.min | 89 |
| corresponding_author_ids | https://openalex.org/A5088186128 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 8 |
| corresponding_institution_ids | https://openalex.org/I4210095959 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8299999833106995 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.69553503 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |